George Jerkovich, MD
Psychiatry · Salina, KSNPI 1578549200
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $957 and has fallen 82.5% since, to $167 in 2024.
Across 208 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$501
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$495
- Otsuka America Pharmaceutical, Inc.$426
- Johnson & Johnson$390
- Alkermes, Inc.$313
- Lundbeck LLC$301
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,628100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $501 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $495 |
| Otsuka America Pharmaceutical, Inc. | 15 | $426 |
| Johnson & Johnson | 18 | $390 |
| Alkermes, Inc. | 9 | $313 |
| Lundbeck LLC | 17 | $301 |
| Sunovion Pharmaceuticals Inc. | 22 | $297 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $241 |
| Neurocrine Biosciences, Inc. | 12 | $171 |
| Teva Pharmaceuticals USA, Inc. | 7 | $151 |
| Tris Pharma Inc | 4 | $68 |
| Acadia Pharmaceuticals Inc | 4 | $64 |
| Corium, LLC | 3 | $56 |
| Ironshore Pharmaceuticals Inc. | 2 | $31 |
| Biogen | 1 | $19 |
| Neos Therapeutics, LP | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
| Sage Therapeutics, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$400
- CAPLYTA$121
- ABILIFY ASIMTUFII$112
- ABILIFY MAINTENA$112
- SPRAVATO$105
How this compares
$3,628 in reported general payments places this provider in the 80th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 13 | $90,559 |
| VraylarCariprazine Hcl | 22 | $50,929 |
| RexultiBrexpiprazole | 23 | $33,565 |
| CaplytaLumateperone Tosylate | 21 | $16,303 |
| FetzimaLevomilnacipran Hcl | 13 | $6,561 |
| VyvanseLisdexamfetamine Dimesylate | 16 | $6,248 |
| Bupropion XlBupropion Hcl | 46 | $5,090 |
| ViibrydVilazodone Hcl | 12 | $4,099 |
| Aripiprazole | 74 | $3,293 |
| Lisdexamfetamine Dimesylate | 12 | $3,153 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 113 | $3,082 |
| Asenapine Maleate | 16 | $2,921 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 39 | $2,187 |
| Duloxetine Hcl | 92 | $2,007 |
| Olanzapine | 40 | $1,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $151 | $90,55913 claims |
| AbbVieVraylar, Fetzima, Viibryd | $501 | $61,58947 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $426 | $33,56523 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $495 | $16,30321 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $241 | $6,24816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Salina
- James OwensSalina$433K
- David WichmanManhattan$613K
- Kevin MaysLeawood$548K
- Sheldon PreskornWichita$498K
- Sasha HamdaniOverland Park$104K
- Christine GlennKansas City$58K
- Heidi OgdenWichita$55K
- Mark RomereimHays$41K
- Patrick StangGreat Bend$28K
- Ralph BharatiWichita$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.